(Q34316206)

1 August 2017

1 reference

title

Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives (English)

1 reference

inflammatory bowel diseases

1 August 2017

main subject

0 references

author name string

Blam ME

series ordinal

1

1 reference

1 August 2017

Stein RB

series ordinal

2

1 reference

1 August 2017

Lichtenstein GR

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

The American Journal of Gastroenterology

1 August 2017

published in

1 reference

1 August 2017

volume

96

1 reference

1 August 2017

issue

7

1 reference

1 August 2017

page(s)

1977-1997

1 reference

Human immunodeficiency virus infection and Crohn's disease: the role of the CD4 cell in inflammatory bowel disease

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Tumor necrosis factor receptor-mediated signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Tumour necrosis factor signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Long term safety of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Use of a push enteroscope improves ability to perform total colonoscopy in previously unsuccessful attempts at colonoscopy in adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Chemokines and cytokines in inflammatory bowel disease and their application to disease treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Impaired On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich Elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Tumour necrosis factor alpha in stool as a marker of intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Thalidomide in oral Crohn's disease refractory to conventional medical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Severe neonatal polycythaemia after third stage of labour underwater

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Protein kinase C-dependent effects on leukocyte migration of thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03931.X

10.1111/J.1572-0241.2001.03931.X

21 January 2018

Identifiers

DOI

0 references

1 reference